FDA 1 hour ago Trump Backs FDA Push to Fast-Track Psychedelic Treatments Trump has vowed to push FDA to expedite psychedelic drug development. fda
FDA 2 days ago RevMed Doubles Phase 3 Survival With Pan-RAS Drug at AACR25 Revolution Medicines' pan-RAS inhibitor delivered a landmark Phase 3 survival readout at AACR25 that doubled survival, setting off what the oncology field… fda
FDA 2 days ago Merck Hits 55% NSCLC ORR With MK-2010, Won't Commit to Phase 3 Merck's MK-2010 posted a 55% unconfirmed overall response rate among 11 previously untreated PD-L1-positive non-small cell lung cancer patients, the first… fda
Deals 2 days ago Raised $625M at $16 a Share, Kailera Tops Moderna's 2018 IPO Record Kailera Therapeutics priced just under 40 million shares at $16 apiece Friday, pulling in $625 million on its Nasdaq debut under KLRA. deals
Deals 4 days ago Revolution Doubles Offering to $2B at $142 After Daraxonrasib Phase 3 Win Revolution Medicines is raising $2 billion in a stock offering priced at $142 per share, up from the $1 billion it announced Monday, hours after reporting… deals
FDA 6 days ago Doubles PDAC Survival: Revolution Jumps 40% on Daraxonrasib Phase 3 Data Revolution Medicines shares jumped to $134.80 Monday, up nearly 40%, after daraxonrasib delivered overall survival of 13.2 months in metastatic pancreatic… fda
FDA 6 days ago FDA Cleared Filspari for FSGS Despite Phase 3 Fail, Opening $2B Market FDA cleared Filspari for focal segmental glomerulosclerosis on Monday, making Travere Therapeutics' endothelin blocker the first and only approved drug for… fda
FDA 6 days ago IDEAYA Targets FDA for Darovasertib After Phase 3 Doubles PFS to 6.9 Months Darovasertib, IDEAYA Biosciences and Servier's PKC inhibitor for metastatic uveal melanoma, more than doubled median progression-free survival in its Phase… fda
FDA Apr 13, 2026 Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the… fda
FDA Apr 13, 2026 Revolution Medicines' Daraxonrasib Succeeds in Phase 3 Registrational Trial Daraxonrasib succeeded in a Phase 3 registrational trial for pancreatic cancer patients, Revolution Medicines reported Monday. fda
FDA Apr 13, 2026 Cleared Phase 3: Daraxonrasib Hits 13.2-Month OS in Pancreatic Cancer Daraxonrasib cleared both primary endpoints in a phase 3 trial for previously treated metastatic pancreatic cancer, Revolution Medicines reported April 13. fda
Deals Apr 13, 2026 Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical… deals
FDA Apr 13, 2026 GSK Races mo-rez Into 5 Phase 3 Trials After 62% Ovarian ORR GSK is sending mocertatug rezetecan (mo-rez) into five phase 3 trials after phase 1b data posted a 62% confirmed overall response rate in platinum-resistant… fda
FDA Apr 13, 2026 FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval FDA cleared Foundayo eight days ago, and Eli Lilly was ready: the company pre-stocked $1.5 billion worth of the pill back in February, months before… fda
FDA Apr 12, 2026 Bets Five Phase 3 Studies on Hansoh ADC: GSK Targets Gynecological Cancers GSK is planning five Phase 3 studies for an antibody-drug conjugate it licensed from Chinese partner Hansoh Pharma, targeting gynecological cancers. fda
Deals Apr 8, 2026 Gilead Spends $14.77B on Three Deals, Then Hits Pause Gilead bought Arcellx, Ouro, and Tubulis for $14.77B in under ten weeks. CFO says further big deals are unlikely this year, but the door stays open. deals
FDA Apr 8, 2026 Lilly's Foundayo Clears FDA; Novo's Oral Wegovy Holds 5-Point Efficacy Lead Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts. fda
FDA Apr 7, 2026 Amgen's Tepezza Just Got Injectable Data. So Did Viridian. Amgen's subcutaneous Tepezza cleared Phase 3 as Viridian Therapeutics competes in the same thyroid eye disease market. Both are racing to file with FDA. fda
FDA Apr 7, 2026 Lunsekimig Fails Eczema Phase 2, Leaving Dupixent Without a Successor Sanofi's lunsekimig cleared asthma and nasal polyp trials but failed its eczema Phase 2, leaving Dupixent without a clear successor as its patent cliff nears. fda
FDA Apr 5, 2026 Lipocine's PPD Drug Fails Phase 3, Stock Craters 77% Lipocine's oral brexanolone failed Phase 3 for postpartum depression, wiping 77% off its stock. The pill version of Zulresso didn't work. fda
